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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.03.001BACKGROUND: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) remained until
recently the molecular genetic abnormality associated with the worst outcome. Hematopoietic stem cell trans-
plant (HSCT) was considered the treatment of choice, however, recent data have indicated that chemotherapy
plus tyrosine kinase inhibitor (TKI) maybe an alternative effective therapy.
METHODS: We conducted a retrospective analysis of children (<18 years) with Ph+ ALL who were treated at
King Hussein Cancer Center (KHCC) from January 2003 till December 2011.
RESULTS: Over a 9 year period, 411 children were diagnosed and treated for ALL at KHCC. Twenty three
(6.6%) had Ph+ ALL; 16 males and 7 females. Median age at diagnosis was 9.5 years (range 1.67–17). The
median white blood cell count was 58.6 · 103/lL (range 1.6–459). Twelve patients underwent HSCT from
a full matched related donor; and 10 were treated with intensive chemotherapy plus TKI (imatinib). Those
who underwent HSCT were significantly older (P = 0.004) and had a higher leukocyte count at diagnosis
(P = 0.53). After a median follow up of 42.2 months (range 12.7–107), the estimated 5 year event free
survival (EFS) and overall survival (OS) were 75% and 91.6%, respectively, for those who underwent
HSCT as primary therapy and 49.3% and 83.3%, respectively, for those treated with chemotherapy plus
imatinib. There was no significant difference in EFS (P = 0.98) or OS (P = 1) between the two treatment
modalities.
CONCLUSIONS: Our results indicate that chemotherapy plus TKI may be a reasonable treatment option
for some children with Ph+ ALL.The probability of curing children with acutelymphoblastic leukemia (ALL) with currenttreatment regimens has exceeded 80%.1–6
Although some adverse prognostic features have lost
their clinical signiﬁcance with improvement in therapy
using a risk-adapted approach; others remain associ-
ated with poor outcome. The translocation t(9;22)
Philadelphia chromosome remained until recently
the molecular genetic abnormality that is associated
with the worst outcome.7–9 While Philadelphia chro-
mosome (Ph) is present in about 40% of adult ALL, itHeonly represents 3–5% of childhood ALL.1,7 Intensive
chemotherapy cures less than 30%, while hematopoi-
etic stem cell transplant (HSCT) from a matched re-
lated donor has raised the cure rate to about 60%.8
Findings of studies suggest that matched unrelated
donor or cord blood transplantation produce results
that are comparable to those obtained with matched
related donor transplantation.9 The development of
the tyrosine kinase inhibitor (TKI) imatinib mesylate
that target the BCR–ABL fusion protein produced by
the Ph chromosome has revolutionized the treatmentmatol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
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of chronic myelogenous leukemia (CML).6 Imatinib
monotherapy has produced a high response rate in
Ph+ ALL but the responses were transient with
recurrences within months.10 Subsequent trials in
adults with Ph positive ALL using imatinib as front
line treatment combined with chemotherapy either
concurrently or sequentially has improved outcome
signiﬁcantly.11,12 Transplant candidates had a better
chance of receiving allogeneic transplantation with
imatinib-combined regimen.12,13 In a children’s oncol-
ogy group (COG) study, continuous imatinib in addi-
tion to intensive chemotherapy has produced in a
cohort of 50 patients 3-year event free survival
(EFS) of 80%, similar to those who underwent
matched-sibling donor transplantation.3
At the King Hussein Cancer Center (KHCC),
children with Ph+ ALL are offered HSCT from an
HLA-matched donor in ﬁrst remission. Those with
no available donor or who decline HSCT are treated
with continuous imatinib combined with intensive
chemotherapy. In this report, we present their treat-
ment results.PATIENTS AND METHODS
We retrospectively reviewed the medical records of
children below 18 years of age diagnosed with Ph+
ALL and treated at KHCC from January 2003
through December 2011.
Diagnosis of Ph+ ALL was based on ﬂuorescence
in situ hybridization (FISH) and cytogenetic analysis
done on the bone marrow obtained at the time of
diagnosis. All children were treated according to theHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comKHCC ALL-1102 protocol, a locally adapted ALL
therapy based on St. Jude Children Research Hospital
protocols (a hybrid of total XIII and total XV proto-
cols).14 According to our protocol, patients with Ph+
ALL were treated on the high risk arm.15
Chemotherapy
Treatment included three phases: Five week remission
induction phase with a seven drug regimen [prednis-
olone, vincristine, daunorubicin, cytarabine, 6-mer-
captopurine (6MP), cyclophosphamide, and L-
asparaginase], (Figure 1). Consolidation phase [four
cycles of high-dose methotrexate (MTX) at a dose
of 4 g/m2, given as a 24-h infusion with leucovorin
rescue, 2 weeks apart, and daily oral 6MP (50 mg/
m2)] (Figure 2). The last phase was a maintenance
phase which consisted of extended weekly L-aspargin-
ase administration followed by rotating pairs of drugs
(cyclophosphamide–cytarabine, etoposide–cytarabine,
vincristine–dexamethasone, and 6MP–MTX). The
6MP dose was 50 mg/m2/day in the ﬁrst 20 weeks
of maintenance therapy increased to 75 mg/m2/day;
the MTX dose was 20 mg/m2 PO weekly. The target
absolute neutrophil count was between 300 and
1500 · 103/lL.
Two courses of 3-week re-induction were given on
weeks 7 and 17 of maintenance therapy. Induction I
consisted of vincristine, doxorubicin, dexamethasone,
and L-asparaginase. High-dose cytarabine was adminis-
tered in induction II.Dexamethasonewas administered
in weeks one and three to minimize osteonecrosis.
All children with Ph+ ALL and have fully
matched related donor were referred to HSCT afterFigure 1. ALL-1102 – induction.
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Figure 3. Intensification chemotherapy.
Figure 2. ALL-1102, consolidation.
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they were continued on chemotherapy.
The intensiﬁcation course consisted of high dose
cytarabine, etoposide, dexamethasone, and L-asparagi-
nase (Figure 3).
Bone marrow examination, FISH, and PCR (poly-
merase chain reaction) evaluation for Ph chromosome
and BCR/ABL gene product were performed on all
children before HSCT.
Central nervous system (CNS) prophylaxis con-
sisted of triple intrathecal therapy (methotrexate, cyt-
arabine, and hydrocortisone) irrespective of the CNS
status; the total doses administered were 25 and no
radiation. Imatinib mesylate was started on day 15
of remission induction at a dose of 340 mg/m2/day
orally and it was continued until the end of therapy
or until the time of HSCT. The total duration of
treatment was 2.5 years for females and 3 years for
males.
Stem cell transplantation
Supportive care: All patients were hospitalized for
their transplant in the bone marrow transplant unit
at high-efﬁciency particulate air (HEPA) ﬁltered
rooms. They all received antimicrobial prophylaxis
against Pneumocystis carinii, Herpes virus, and fungal
infections with trimethoprim–sulfamethoxazole, acy-
clovir, and ﬂuconazole, respectively. Cytomegalovirus
(CMV) reactivation was monitored by the pp65 anti-
genemia test weekly starting from the time of neutro-
phil engraftment till 100 days post transplantation.
Treatment with gancyclovir was initiated when twoHeconsecutive positive antigenemia of more than two
cells/250 white blood cells documented, until a min-
imum of two negative tests was obtained.
Conditioning regimen and graft versus host disease
(GVHD) prophylaxis: All patients received myeloab-
lative conditioning that included fractionated total
body irradiation of 12 Gy delivered in six fractions
over 3 days followed by cyclophosphamide 60 mg/kg
infused over 1 h daily for 2 days. All patients received
GVHD prophylaxis consisted of a short course of
MTX (15 mg/m2 at days +1, 3 and 6) and intrave-
nous cyclosporine starting from day-3. Patients were
switched to oral cyclosporine whenever they were able
to tolerate oral medications. Cyclosporine was gradu-
ally tapered off starting at day 100 post transplant and
then stopped completely at day 180 post transplant if
there was no GVHD.
Response criteria
Minimal residual disease (MRD) evaluation: A MRD
panel was selected according to the patient’s previ-
ously determined immunophenotype. The following
monoclonal antibody combinations CD10/CD19/
CD45/CD34 and CD20/CD45/CD19 were per-
formed on each patient’s marrow sample and
CD33/CD13/CD45/CD19 was performed if the pa-
tient’s leukemic cells previously expressed a myeloid
marker. CD45 and side-scatter were used for the gat-
ing strategy. The result was reported as <0.01% for
the negative results and as a percentage for the posi-
tive ones. MRD evaluation was performed on day
15 of induction and was repeated on day 22 only ifmatol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
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day 15 showed 5% or more leukemic blasts, otherwise,
it was performed at the end of induction.
Day 15 induction bone marrow evaluation: Bone
marrow (BM) remission status was evaluated on day
15 of remission induction and was deﬁned as the pres-
ence of leukemic blasts by morphology (before July
2005) and minimal residual disease (MRD) (after July
2005) of less than 5%.
End of induction BM evaluation: Complete remis-
sion at the end of induction was deﬁned as no leuke-
mic blasts by morphology and an MRD of less than
1%.
Statistical methods
Demographic parameters were summarized as means
and ranges for continuous variables, or frequency and
percentages for categorical variables. Comparisons be-
tween categorical variables were carried out using the
Chi-square test and Fisher’s exact test as appropriate.
Survival and event-free-survival curves were presented
using the Kaplan–Meier method and compared with
standard error (SE). Comparisons in survival and
event free-survival were performed using the Log rank
test. P value 0.05 was considered statistically signif-
icant. All analyses were carried out using SAS version
9.1 (SAS Institute Inc., Cary, NC).RESULTS
Over a 9 year period, 411 children were diagnosed
and treated for ALL at KHCC, out of these 23 had
Ph+ ALL (6.6%). The median age at diagnosis was
9.5 years (range 1.67–17). There were 16 males and
7 females, with a male to female ratio of 2.3:1. The
initial leukocyte count (WBC) at diagnosis ranged
from 1.6 to 459 · 103/lL with a median count of
58.6 · 103/lL. The majority of patients (91.3%)
had pre-B cell immunophenotype; two had T-cell
phenotype. Twenty children had CNS I status, one
had CNS II, and two had CNS III status (7th nerve
palsy) (Table 1).
Of the 23 children, one died early in induction due
to sepsis. Twelve patients underwent allogeneic
HSCT from a full matched related donor; the
remaining 10 had no full matched donor (n = 9) or
declined transplant (n = 1) and were treated with
intensive chemotherapy plus imatinib mesylate (Table
2).
For the 12 children who underwent HSCT, there
were 9 males and 3 females; the median age at diagno-
sis was 12.5 years (range 4.2–17), and the median ini-
tial WBC was 84.8 · 103/lL (range 1.6–459).
Evaluation on day 15 showed remission by morphol-Hematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comogy (M1) in 11 (91.7%); one failed to achieve remis-
sion (M2). All patients were in remission (M1) at the
end of induction (Table 3). Bone marrow examination
prior to HSCT was in M1 and FISH and BCR/ABL
were negative in all patients.
A total of four patients (33%) developed grade II–
IV acute GVHD, one of them died with severe skin,
gut, and liver acute GVHD. Chronic GVHD devel-
oped in three patients (27%), one limited and two
extensive; all were controlled and resolved with ﬁrst
line treatment. At the last follow up, all surviving pa-
tients are off immune suppression.
Of the 10 children who were treated with intensive
chemotherapy plus imatinib mesylate, 6 were males
and 4 were females; the median age was 4.4 years
(range 1.7–11.9) and the median initial WBC was
23.6 · 103/lL (range 3.5–340). BM evaluation at
day 15 of induction showed complete remission by
morphology (M1) in seven patients, two failed to
achieve remission (M2), and one had no available
BM evaluation. All patients achieved complete remis-
sion at the end of induction by bone marrow mor-
phology (M1) (Table 3).
After a median follow up of 42.2 months, the esti-
mated 5-year overall survival rate (OS) for the whole
group was 83 ± 9.5%. Based on treatment modality,
the estimates of event-free survival (±SE) ﬁve years
after diagnosis was 75 ± 12.5% for patients who
underwent HSCT and 49.3 ± 22.8% for those treated
with chemotherapy only (P = 0.9) (Figure 4A). The
5-year OS rate for patients who underwent HSCT
in ﬁrst remission (CR1) was 91.6 ± 7.9%, while pa-
tients who were treated with chemotherapy only
had an 83.3 ± 15.2% OS (P = 1) (Figure 4B).
Relapses and deaths
Of the 23 patients, ﬁve relapsed. Two patients re-
lapsed after HSCT from a fully matched related do-
nor 10 and 11 months post transplant; both are in
clinical and molecular remission 25 and 53 months,
respectively, after treatment with TKI (dasatinib in
one, and imatinib in the other). Three patients re-
lapsed after treatment with intensive chemotherapy
and imatinib mesylate; the ﬁrst developed asymptom-
atic isolated CNS relapse at the end of therapy evalu-
ation. He was subsequently treated with additional
intensive chemotherapy, cranial radiation, and dasati-
nib; but experienced a second relapse (BM)
18 months after his ﬁrst relapse. The second devel-
oped isolated bone marrow relapse one year after ﬁn-
ishing treatment; he underwent HSCT from his
father (one antigen mismatch), and remained in
remission 10 months after HSCT. The third patient37
Table 1. Patients' characteristics.
Gender
Male 16 (69.6%)
Female 7 (30.4%)
Age (years)
Median 9.5
Range 1.67–17
WBC · 103/lL
Median 58.6
Range 1.6–459
Follow up (months)
Median 42.2
Range 12.7–107
Immunophenotype
Pre B cell 21 (91.3%)
T cell 2 (8.7%)
CNS
I 20 (87%)
II 1(4.3%)
III 2 (8.7%)
Treatment
Bone marrow transplantation 12 (54.5%)
Chemotherapy 10 (45.5%)
WBC: White blood count, CNS: central nervous system.
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motherapy; he underwent HSCT from a related cord
blood but experienced a second bone marrow relapse
and died of disease. One child died of severe GVHD
96 days post HSCT.DISCUSSION
In this report we reviewed children treated for Ph+
ALL at KHCC over a 9 year period. In our cohort
of patients, improved survival of children with Ph+
ALL was evident compared to the old published
data.3,6,9,12 Advances in HSCT techniques, betterHeselection of donors, and the introduction of TKI have
contributed to the overall improvement in the out-
come of this difﬁcult subset of patients.
Patients younger than 10 years with initial leuko-
cyte count of less than 50 · 103/lL at the time of
diagnosis had better long term disease free survival.7
In our study, the median age of patients was 9.5 years
and the median initial WBC count was 58.6 · 103/
lL, possibly contributing to our good overall results.
There was no signiﬁcant difference in the EFS and
OS between the patients who underwent HSCT
compared to those treated with chemotherapy only.
However, those who underwent HSCT were older
and had a higher leukocyte count at diagnosis. This
observation may have impacted the outcome and con-
ﬁrms the need for more randomized controlled stud-
ies to identify patients who would beneﬁt from
allogeneic HSCT as the primary therapy versus those
who would be adequately treated using TKI plus che-
motherapy only.8
One of the reasons for the poor outcome for pa-
tients with Ph+ ALL was the higher rate of induction
remission failure. In a retrospective study by Arico
et al, the rate was reported to be 18% in comparison
to 2–3% failure rate in a series of unselected patients
with childhood ALL.9 In the era of using TKI like
imatinib, the rate of remission induction in Ph+
ALL patients has improved dramatically.13,16 All
our patients achieved complete remission at the end
of induction; this is in agreement with the new re-
ported results from the European studies.17
Another cause of treatment failure in Ph+ ALL
patients was the high rate of relapse.12 Historically
the relapse rate was highest early in the course of
treatment. In our study, ﬁve children had relapsed;
two were treated primarily with HSCT and relapsed
during the ﬁrst year post transplant; three were trea-
ted with imatinib plus chemotherapy and relapsed
during the third and fourth years (BM in 2, CNS
in 1). Use of Imatinib could be a factor in the occur-
rence of relapses late in the course of the disease.
The addition of imatinib to the intensive chemo-
therapy was found to be well tolerated.9–13 Imatinib
was started at day 15 of induction at a dose of
340 mg/m2 and continued till the end of therapy. Ma-
jor toxicities were limited; one child developed exces-
sive GI toxicity and imatinib was replaced by
dasatinib; a second child, a member of a twin, experi-
enced a signiﬁcant delay in growth. No dose reduction
was necessary.
The impact of using TKI after HSCT is contro-
versial with conﬂicting data.18–20 The COG study
showed no difference in EFS for 6 months of TKImatol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
Table 2. Patient characteristic, response and outcome.
Patient No. Sex Age (years) Immunotype WBC · 109 CNS D15 D35 Treatment Duration of remission (months) Status (follow up) (months)
1 M 14 Pre B 7.9 III CR CR BMT _ NED (89)
2 M 17 Pre B 110.9 I CR CR BMT _ NED (82)
3 M 4 Pre B 244 I CR CR CTX Relapse/BM(22) DOD (44)
4 M 14 T cell 376 III NA NA NA _ Died (0.42)
5 F 11 Pre B 10.4 I NA CR CTX _ NED (99)
6 M 17 Pre B 1.6 I CR CR BMT _ NED (103)
7 M 2 Pre B 3.5 I Non CR CTX Relapse/BM(47) NED (60)
8 F 3.5 Pre B 339.7 I CR CR CTX _ NED (59)
9 M 7 Pre B 86.5 I Non CR CTX _ NED (43)
10 M 12 Pre B 4.7 I CR CR CTX _ NED (35)
11 F 15 Pre B 139 I CR CR BMT _ NED (33)
12 M 14 Pre B 4.1 I CR CR BMT _ NED (53)
13 M 4.5 Pre B 21.1 I CR CR CTX Relapse/CNS(36) NED (52)
14 M 4 Pre B 23.9 I CR CR BMT Relapse/BM(11) NED (53)
15 F 10 T cell 459 I CR CR BMT _ NED (35)
16 M 6 Pre B 26 I CR CR CTX _ NED (32)
17 F 1.5 Pre B 7.8 I CR CR CTX _ NED (32)
18 M 16.5 Pre B 2.2 I CR CR BMT Relapse/BM(10) NED (25)
19 M 5.5 Pre B 58.6 I CR CR BMT _ NED (13)
20 M 9.5 Pre B 132 I Non CR BMT _ NED (12)
21 F 3 Pre B 229 I CR CR CTX _ NED (9)
22 M 8.5 Pre B 348 I CR CR BMT _ NED (16)
23 F 11 Pre B 338 II CR CR BMT _ Died (11)
Age: Age at diagnosis, CNS: central nervous system, D15: bone marrow evaluation by morphology at day 15 induction, D35: bone marrow evaluation at day 35, NED: no evidence of disease, BMT:
bone marrow transplant, CTX: chemotherapy, DOD: died of disease.
HEMATOPOIETIC STEM CELL TRANSPLANT brief reportmaintenance following HSCT compared with histor-
ical transplant outcome.3 In our patients, we did not
use TKI following HSCT. It is of interest that two
of the children who relapsed after HSCT responded
to TKI and are still in continuous remission.
Additional studies are needed to ﬁnd out if the use
of second generation TKI (like dasatinib and niloti-
nib) will improve the outcome further. Both agents
are more potent inhibitors of BCR–ABL kinase activ-
ity,6 and dasatinib may have the added advantage of
better CNS penetration.21
Our study has some limitations; the number of pa-
tients is small and the follow up period is relatively
short. Log Rank test may fail to detect the differences
in survival time due to small sample size. The lowHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comincidence of Ph+ ALL and the shortage of large pro-
spective studies make the optimal treatment strategy
for this high risk group unclear.
In conclusion, outcome of children with Ph+ ALL
has improved signiﬁcantly. The best treatment option
is still not clear. A subset of patients may beneﬁt from
treatment with chemotherapy plus TKI. This creates
an opportunity for our regional cancer institutions to
initiate a multicenter study.Acknowledgment
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Table 3. Comparison between patient's characteristics, response, and outcome according to treatment modalities.
Characteristic Stem cell transplant Chemotherapy P value
Gender, n (%)
Male 9 (75%) 6 (60%) 0.65
Female 3 (25%) 4 (40%)
Age (years)
Median (range) 12.5 (4.2–17.0) 4.4 (1.7–11.9) 0.0041
WBC (·103/ll)
Median (range) 84.8 (1.6–459) 23.6 (3.5–340) 0.53
D15-morphology
CR 11 (91.7%) 7 (70%) 0.36
Non remission 1 (8.3%) 2 (20%)
NA 1 (10%)
D35-morphology
CR 12 (100%) 10 (100%) NA
5-Year EFS 75% 49.3% 0.98
5-Year OS 91.6% 83.3% 1.0
CR: Complete remission, NA: not available, EFS: events free survival, OS: overall survival.
Figure 4. 5-year event free survival and overall survival according to treatment modality.
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